近年来，作为乳腺癌研究新热点，纳米给药系统治疗策略引起了广泛关注。然而，提高该系统中药物对肿瘤组织的靶向性、实现实时精确地监控药物体内途径、克服化疗的耐药性等也成为了亟待解决的问题。据文献报道，乳腺癌细胞表面高度表达Recepteur d’Origine Nantais（RON）酪氨酸激酶受体，而正常乳腺细胞表达较少，近期研究发现一种新型多肽（P6）能够与乳腺癌细胞表面RON受体特异性结合，且具有很高的亲和力，提示P6多肽有介导纳米给药系统靶向乳腺癌细胞并发挥治疗作用的潜力。本课题拟利用P6多肽修饰的氧化介孔碳球（OMCN）作为药物载体同时又作为光声成像和光热治疗的材料，载入化疗药物阿霉素（DOX），制备成一种治疗乳腺癌的纳米给药系统（P6-PEG-OMCN/DOX）。该系统有望集靶向识别、荧光/光声双模态成像及化疗-光热治疗多功能于一体，为乳腺癌的治疗开拓新途径。

In recent years, the nano drug delivery system has caused wide concern in breast cancer therapy. However, it is quite a challenge to enhance tumor targeting efficiency, realize the real-time monitoring of in vivo distribution and overcome tumor resistance to single chemotherapy. Recepteur d’Origine Nantais (RON) tyrosine kinase receptor has been reported to be highly expressed on breast cancer cells, but is sub-expressed on normal mammary cells. A recent study found a novel peptide (P6) can specifically bind to RON tyrosine kinase receptor with high affinity. This suggests that P6 peptide has the potential to mediate nano drug delivery system targeting to breast cancer cells. In this project, P6 peptide will be covalently conjugated to oxidized mesoporous carbon nanospheres (OMCN) to act as a nanocarrier for encapsulating DOX and an agent for photoacoustic (PA) imaging and photothermal therapy (PTT), yielding a multifunctional nano drug delivery system (P6-PEG-OMCN/DOX). This project may concentrate targeted recognition, fluorescence/PA bimodal imaging and chemo-PTT therapeutic model on one system and hence provide a new way for breast cancer therapy.